| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Alentemol targets dopamine receptors, particularly the D₂ and D₃ receptor subtypes. As a dopamine receptor antagonist, it blocks the binding of dopamine to these receptors, reducing dopaminergic neurotransmission. This is the mechanism underlying its antipsychotic effects. The compound may also have affinity for serotonin (5-HT) receptors, contributing to its pharmacological profile.
|
|---|---|
| ln Vitro |
In vitro, Alentemol shows antagonist activity at dopamine D₂ and D₃ receptors. It inhibits dopamine-stimulated cAMP accumulation in cells expressing these receptors. The compound may also show affinity for 5-HT₂A receptors. Specific IC50 or Ki values are not detailed in available literature. Alentemol is a potent dopamine receptor antagonist with a profile similar to atypical antipsychotics.
|
| ln Vivo |
In vivo, Alentemol has been studied in animal models of psychosis. It may inhibit apomorphine-induced or amphetamine-induced hyperactivity in rodents. The compound may also show activity in conditioned avoidance response tests. Detailed pharmacokinetic and clinical efficacy data are limited. Alentemol has been investigated for the treatment of schizophrenia.
|
| Enzyme Assay |
Dopamine D₂ and D₃ receptor binding affinity is assessed using radioligand binding assays with [³H]-spiperone or [³H]-raclopride as tracers. Membrane preparations from cells expressing D₂ or D₃ receptors are incubated with varying concentrations of Alentemol and a fixed concentration of radioligand. Non-specific binding is determined using haloperidol or butaclamol. Ki values are calculated from competition curves.
|
| Cell Assay |
For functional assays, cells expressing D₂ or D₃ receptors are treated with Alentemol at varying concentrations and stimulated with dopamine. cAMP accumulation (or inhibition of forskolin-stimulated cAMP) is measured by ELISA. IC50 values for inhibition of the dopamine response are calculated. For antipsychotic activity screening, the compound may be tested for inhibition of dopamine-induced calcium mobilization or reporter gene expression.
|
| Animal Protocol |
For in vivo efficacy, rodents are administered Alentemol orally or intraperitoneally at doses of 0.1-10 mg/kg. Apomorphine-induced climbing behavior or amphetamine-induced hyperactivity is assessed. Conditioned avoidance response tests are performed to evaluate antipsychotic-like activity. Catalepsy is assessed to evaluate extrapyramidal side effect liability. Pharmacokinetic parameters are determined from plasma concentration measurements.
|
| Additional Infomation |
Alentemol is a tricyclic hydrocarbon fused in both ortho and pericyclic positions.
|
| Molecular Formula |
C19H25NO
|
|---|---|
| Molecular Weight |
283.4079
|
| Exact Mass |
283.194
|
| CAS # |
112891-97-1
|
| Related CAS # |
112892-81-6 (HCl);112891-97-1;112892-51-0 (HBr);
|
| PubChem CID |
60574
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.1g/cm3
|
| Boiling Point |
464.2ºC at 760 mmHg
|
| Flash Point |
238.3ºC
|
| Vapour Pressure |
3.08E-09mmHg at 25°C
|
| Index of Refraction |
1.614
|
| LogP |
4.134
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
21
|
| Complexity |
326
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCN(C1CC2=CC=CC3=CC(=CC(=C23)C1)O)CCC
|
| InChi Key |
TWUJBHBRYYTEDL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H25NO/c1-3-8-20(9-4-2)17-10-14-6-5-7-15-12-18(21)13-16(11-17)19(14)15/h5-7,12-13,17,21H,3-4,8-11H2,1-2H3
|
| Chemical Name |
5-(dipropylamino)-5,6-dihydro-4H-phenalen-2-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5285 mL | 17.6423 mL | 35.2846 mL | |
| 5 mM | 0.7057 mL | 3.5285 mL | 7.0569 mL | |
| 10 mM | 0.3528 mL | 1.7642 mL | 3.5285 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
